Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Obtaining Strong Price From BMS, Medarex Also Ameliorates Significant Pipeline Pressure

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol's acquisition offer of $16 per share is certainly generous, but Medarex has a lengthy and promising pipeline to offer and one which would have needed deep pockets down the road.
Advertisement

Related Content

With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
BMS Files Ipilimumab With FDA And EMA, Positioning It For Launch Next Year
ASCO Highlights In Brief
J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO

Topics

Advertisement
UsernamePublicRestriction

Register

PS069764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel